Please assess the completion status of the following clinical trial:

Trial Title: Determining the Efficacy and Value of Immunotherapy on the Likelihood of Peanut Tolerance: The DEVIL Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 9-36 months of either sex, any race, any ethnicity at the time of the initial visit~* EITHER a positive skin prick test to peanuts or in vitro \[CAP-FEIA\] peanut immunoglobin E (IgE) level in the blood \> 0.35 kU/L PLUS a history of a clinical allergic reaction (defined as significant clinical symptoms occurring within 60 minutes after ingesting peanuts) within 6 months of screening~* OR a positive prick skin test to peanuts and in vitro \[CAP-FEIA\] peanut IgE level \> 5 kU/L when there is no history of allergic reaction and no known peanut exposure~* Provision of signed informed consent~* Development of symptoms characteristic of IgE-mediated food allergy (urticaria, angioedema, respiratory distress/wheeze/cough, vomiting/diarrhea, anaphylaxis) during initial oral food challenge~Exclusion Criteria:~* History of severe anaphylaxis to peanut as defined by hypoxia, hypotension, or neurological compromise~* Currently participating in a study using an investigational new drug~* Participation in any interventional study for the treatment of food allergy in the past 12 months~* Subjects with a known wheat food allergy will be excluded because of cross contamination of oat with wheat~* Severe atopic dermatitis~* Currently being treated with greater than medium daily doses of inhaled corticosteroids, as defined by the National Heart Lung and Blood Institute (NHLBI) guidelines~* Inability to discontinue antihistamines for skin testing and OFCs

- Gender: ALL
- Minimum Age: 9 Months
- Maximum Age: 36 Months
- Healthy Volunteers: f

Study Arms:
- Peanut oral immunotherapy (Type: EXPERIMENTAL): Newly diagnosed allergic children receiving peanut flour as oral immunotherapy for the treatment of peanut allergy.

Based on this trial design, predict the completion outcome and termination type (if applicable).